Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* vitiligo and surface area involved of less than10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH)~* 6 weeks wash out period from previous treatments will be employed to eliminate any effect from such treatments~Exclusion Criteria:~* Skin dermatoses with Kobner phenomenon~* Lupus erythematous~* Pacemakers~* Hyper-photosensitivity~* Melanoma and non-melanoma skin cancers~* Drugs with photosensitizer side effect~* Radiotherapy~* Pregnancy (by principle, nno study available)~* Diseases that are contagious by contact

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus + excimer light (group A) (Type: ACTIVE_COMPARATOR): group A, will be treated by Tacrolimus 0.1% ointment twice daily and excimer light 308nm twice weekly (exciplex®)
- Tacrolimus (group B) (Type: ACTIVE_COMPARATOR): group B will start on Tacrolimus 0.1% ointment twice daily alone

Based on this trial design, predict the completion outcome and termination type (if applicable).